WallStreetZenWallStreetZen

NASDAQ: FATE
Fate Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

FATE past revenue growth

How has FATE's revenue growth performed historically?
Company
-34.03%
Industry
148.4%
Market
16.96%
FATE's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
FATE's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
FATE's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

FATE earnings and revenue history

Current Revenue
$63.5M
Current Earnings
-$160.9M
Current Profit Margin
-253.3%

FATE Return on Equity

Current Company
-38.2%
Current Industry
-63.5%
Current Market
188%
FATE's Return on Equity (-38.2%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when FATE announces earnings.

FATE Return on Assets

Current Company
-28.4%
Current Industry
2.9%
FATE is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

FATE Return on Capital Employed

Current Company
-34.45%
Current Industry
19.5%
FATE's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

FATE vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
FATE$63.53M-$142.65M-$160.93M+68.05%N/A
CDMO$136.74M-$7.83M-$17.98M+25.75%N/A
TRDA$129.01M$14.90M-$6.69MN/AN/A
KALV$0.00-$107.49M-$108.30M-100.00%N/A
EDIT$78.12M-$164.72M-$153.22M+19.59%N/A
View Top Biotech Stocks

FATE earnings dates

Next earnings date
May 1, 2024

Fate Therapeutics Earnings & Revenue FAQ

What were FATE's earnings last quarter?

On Invalid Date, Fate Therapeutics (NASDAQ: FATE) reported Q4 2023 earnings per share (EPS) of -$0.45, up 22.41% year over year. Total Fate Therapeutics earnings for the quarter were -$44.12 million. In the same quarter last year, Fate Therapeutics's earnings per share (EPS) was -$0.58.

If you're new to stock investing, here's how to buy Fate Therapeutics stock.

What was FATE's earnings growth in the past year?

As of Q2 2024, Fate Therapeutics's earnings has grown year over year. Fate Therapeutics's earnings in the past year totalled -$160.93 million.

What is FATE's earnings date?

Fate Therapeutics's earnings date is Invalid Date. Add FATE to your watchlist to be reminded of FATE's next earnings announcement.

What was FATE's revenue last quarter?

On Invalid Date, Fate Therapeutics (NASDAQ: FATE) reported Q4 2023 revenue of $1.68 million up 96.22% year over year. In the same quarter last year, Fate Therapeutics's revenue was $44.36 million.

What was FATE's revenue growth in the past year?

As of Q2 2024, Fate Therapeutics's revenue has grown -34.03% year over year. This is 182.43 percentage points lower than the US Biotechnology industry revenue growth rate of 148.4%. Fate Therapeutics's revenue in the past year totalled $63.53 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.